drugset
drugset / Trial / NCT01357993

A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

NCT01357993 ↗

Phase 3 Completed 253 enrolled Janssen Pharmaceutical K.K.
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate long-term safety and tolerability of JNS001 at 18 to 72 mg per day in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

Timeline

Start
2011-05
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject JNS001 Unknown 18 mg Oral
Subject JNS001 Unknown 27 mg Oral
Subject JNS001 Unknown 36 mg Oral
Subject JNS001 Unknown 45 mg Oral
Subject JNS001 Unknown 54 mg Oral
Subject JNS001 Unknown 63 mg Oral
Subject JNS001 Unknown 72 mg Oral

Indications

attention deficit-hyperactivity disorder